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  INTRODUCTION 
 Nontypeable  Haemophilus influenzae  (NTHI) is a predominant 
bacterial agent of the prevalent pediatric disease otitis media 
(OM), and is also responsible for multiple diseases of the upper 
and lower respiratory tracts of both children and adults.  1   The 
economic burden of NTHI-induced diseases, including OM, is 
significant because of the treatment and surgical management 
costs.  2  Complications of OM, for example, hearing loss, are asso-
ciated with behavioral, educational, and language development 
delays of this very young population.  3   With the goal to prevent 
NTHI-induced OM, many research efforts have focused on 
the development of vaccines that target outer membrane pro-
teins (OMPs), other surface proteins, and lipooligosaccharide 
expressed by this bacterium.  4  
  Our lab has concentrated on two of the multiple adhesins 
expressed by NTHI: OMP P5 and the type IV pilus (Tfp). 
Specifically, we have designed three vaccine candidates: a 40-mer 
synthetic chimeric peptide immunogen called  “ LB1 ”  that incor-
porates a 19-mer B-cell epitope from OMP P5 that has been 
colinearly synthesized with a T-cell promiscuous epitope from 
measles virus fusion protein;  5   a recombinant protein called 
  “  rsPilA  ”   that represents a mature, N-terminally truncated, 
and soluble PilA subunit protein of the Tfp;  6   and a chimeric 
immunogen called   “  chimV4  ”   in which modified rsPilA serves 
as both immunogen and carrier molecule for a 24-mer epitope 
of OMP P5 that is positioned at its N-terminus.  6   Antibody 
induced by parenteral immunization with any of these 
immunogens confers significant protection against NTHI-
induced OM in a chinchilla model of viral-bacterial superinfec-
tion.  6,7  We now wanted to expand our vaccine delivery strategies 
to develop a noninvasive but potentially equally efficacious 
method, transcutaneous immunization (TCI). 
  TCI, the application of a vaccine onto intact skin, induces 
an immune response by engaging antigen-presenting cells 
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present within the epidermis and dermis, the Langerhan  ’  s cells 
and dermal dendritic cells (DCs), respectively.  8   There  are 
multiple benefits to this immunization route, which include 
the simplicity and noninvasive nature of delivery, reduced cost 
as syringes, needles, and trained medical professionals are not 
required to deliver the vaccine, and the prospect for greater 
vaccine distribution beyond developed countries because of 
typically cheaper production costs.  9   Previous studies show 
that TCI with bacterial or viral proteins and other peptide 
antigens induces an immune response in both animals and 
humans.  10 – 12   Furthermore, via use of animal models, there 
is evidence of protection against subsequent bacterial, viral, 
or toxin challenge.  13 – 16   Whereas parenteral immunization 
elicits primarily a systemic immune response, TCI induces 
both systemic and mucosal immunity.  17   OM is a disease of 
the uppermost respiratory tract, and therefore the ability to 
induce immunity at the mucosae of this anatomical region 
has the potential to reduce, or preferably prevent, the onset of 
disease in the middle ear. 
  NTHI-induced diseases of the respiratory tract, including 
OM, can be chronic and / or recurrent in nature, a consequence 
of biofilms present on the respiratory mucosae.  18   Specific  to 
OM, NTHI biofilms are shown on the middle ear mucosa of 
children  19   and upon gross examination of the middle ear in 
animal models.  20  These bacterial communities are recalcitrant 
to antibiotic treatment and resist immune-mediated clearance. 
Among other NTHI proteins, OMP P5 and Tfp are identi-
fied as components of the biofilm matrix.  21,22   We  therefore 
hypothesized that immunization with NTHI OMP P5- and 
Tfp-directed immunogens could serve to target each element 
  in vivo  , and thus facilitate resolution of OM. Herein, we uti-
lized a chinchilla model of experimental NTHI-induced OM 
to examine the immune response elicited by TCI with NTHI 
OMP P5- and Tfp-directed immunogens when delivered with 
a potent adjuvant, a double mutant of  E. coli  heat-labile entero-
toxin (dmLT).  16   Moreover, we examined the efficacy of TCI 
when utilized in both preventative and therapeutic immuniza-
tion strategies to determine the potential of this noninvasive 
approach to protect against as well as resolve experimental 
NTHI-induced OM.     
  RESULTS   
  Histological analysis of chinchilla pinna 
  Pinnae from naive chinchillas were collected to examine 
the histological organization of this tissue. A cross-section 
of a pinna is shown in   Figure 1  , wherein the epidermis and 
dermis, supported by elastic connective tissue, were discern-
ible on each side of hyaline cartilage that runs central through 
the pinna. Similar to human thin skin, the pinna contained 
hair follicles and sebaceous glands. An abundant stratum 
corneum was visible as the outermost layer of the epidermis. 
Therefore, hydration of this keratinized epithelial layer was 
deemed necessary to enhance the permeability of the skin and 
thus facilitate both entry of topically applied molecules and 
sampling by cutaneous antigen-presenting cells, as has been 
reported.  23    
  TCI before NTHI challenge: resolution of nasopharyngeal 
colonization 
  To examine the ability of TCI with NTHI OMP P5-directed 
candidate   “ LB1, ”   the  Tfp-directed  candidate   “ rsPilA, ”   and  the 
chimeric OMP P5-plus Tfp-directed immunogen   “  chimV4,  ”   
to induce clearance of NTHI from the nasopharynges (NP) of 
challenged chinchillas, periodic NP lavages were performed 
and the recovered fluids cultured to semiquantitate the rela-
tive bacterial load at this anatomical site. Cohorts administered 
any of the three immunogens without adjuvant and the cohort 
immunized with dmLT alone had 10  4  – 5 × 10 6 colony-forming 
unit (CFU) NTHI in NP lavage fluids beginning 3 days after 
challenge, and maintained this bacterial load for the remainder 
of the study period ( Figure 2a ). In contrast, cohorts that received 
rsPilA, LB1, or chimV4 admixed with dmLT demonstrated 2- to 
4-log fewer NTHI within NP lavage fluids on each of days 7, 10, 
and 14 after bacterial challenge, a statistically significant result at 
each time point, compared with cohorts that received respective 
immunogen only or dmLT only (  P     <    0.05).  Moreover,  only  the 
three cohorts that received immunogen plus dmLT eliminated 
NTHI from the NP within 10 or 14 days after challenge. 
 As an additional assessment of efficacy, the relative percentage 
of animals with culture-positive NP lavage fluids was calculated 
for each cohort. At 3 days after NTHI challenge, 100  %   of the 
animals administered immunogen alone or dmLT alone had cul-
ture-positive NP lavage fluids, and at least 5  /  10 (50  %  ) animals 
in each of these four cohorts remained culture positive for the 
entire 14-day study period (  Figure 2b ).  In  contrast,  a  20 – 40 %  
reduction in culture-positive NP lavage fluids was observed 3 
days after NTHI challenge in cohorts that received any of the 
three tested immunogens plus dmLT. Furthermore, at 7 days 
after NTHI challenge, only 1  /  10 (10  %  ) animals in the cohorts 
that  received  LB1    +    dmLT  or  rsPilA    +    dmLT  and  4 / 10  (40 % ) 
animals  within  the  cohort  administered  chimV4    +    dmLT  had 
culture-positive NP lavage fluids, and by 14 days after bacterial 
    Figure 1                        Cross-section through a naive chinchilla pinna stained with 
hematoxylin and eosin. Chinchilla pinna exhibited characteristics of thin 
skin and thus was amenable to transcutaneous immunization (TCI) 
upon hydration of the stratum corneum. Image captured at original 
magnification   ×  10. Ct, connective tissue, D, dermis; Ep, epidermis; 
Hc, hyaline cartilage; Hf, hair follicle and associated sebaceous gland; 
Sc, stratum corneum;  Sg, sebaceous gland.   458  VOLUME 4 NUMBER 4 | JULY 2011 | www.nature.com/mi
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challenge all of these latter cohorts had eliminated NTHI from 
the NP. These data therefore demonstrated that TCI with OMP 
P5- and Tfp-directed candidates, when delivered in combina-
tion with dmLT, resulted in an effective immune response that 
reduced, and then completely eliminated, NTHI from the NP.     
  TCI before NTHI challenge: resolution of experimental OM 
  As a more rigorous assessment of the protection afforded by 
TCI, the same chinchillas as challenged intranasally above 
were also challenged by direct inoculation of the middle 
ears with 1,000     CFU NTHI to initiate active OM. Middle ear 
fluids (MEFs), when present as observed by video otoscopy 
and confirmed by tympanometry, were collected and cultured 
to determine the relative concentration of NTHI within these 
fluids. Within 3 days after challenge, the inoculum of 1,000   CFU 
NTHI had multiplied to 1.1 × 10  7    CFU NTHI in MEFs retrieved 
from animals that received dmLT alone ( Figure 3a ). As 10  8    C F U  
NTHI is typical for sham-immunized chinchillas (alum or 
monophosphoryl lipid A),  24  the observed reduction after receipt 
of dmLT suggested that this adjuvant induced a nonspecific pro-
tective effect. Animals administered LB1, rsPilA, or chimV4 
alone also exhibited an increase in bacterial concentration to 
8.4 × 10 5  – 2.1 × 10 6    CFU NTHI at this time point. Compared with 
receipt of adjuvant alone, fewer NTHI were detected, which 
demonstrated that delivery of any of the three immunogens that 
target NTHI OMP P5 or Tfp induced an enhanced immune 
response. In contrast, at 3 days after direct challenge, an increase 
from 1,000     CFU to approximately 8  ×  10  3  – 8 × 10 4    CFU  NTHI 
was observed in MEFs collected from animals immunized with 
any of the three immunogens delivered with dmLT. Moreover, 
whereas approximately 10  6   to 10  7    CFU  NTHI  was  detected  in 
MEFs collected from animals immunized with only one of three 
immunogens or with dmLT alone between 7 and 14 days after 
challenge, significantly fewer NTHI (approximately 2- to 7-logs 
      Figure 2                        Transcutaneous immunization (TCI) via a preventative regimen induced clearance of nontypeable   Haemophilus influenzae   (NTHI) from the 
nasopharynges (NP) of chinchillas. (  a  ) Colonization kinetics that demonstrated that receipt of rsPilA      +      dmLT, LB1      +      dmLT, or chimV4       +      dmLT resulted 
in rapid clearance of NTHI from the NP relative to the cohorts administered rsPilA, LB1, chimV4, or dmLT alone.   *  Statistically significant compared 
with receipt of respective immunogen-only cohort and dmLT-alone cohort (  P        <      0.05). CFU, colony-forming unit; dmLT, double mutant of   E. coli   heat-
labile enterotoxin; rsPilA, recombinant soluble PilA. (  b  ) Percentage of colonized NP per cohort showing a reduction in colonization after receipt of 
LB1      +      dmLT, rsPilA      +      dmLT, or chimV4      +      dmLT compared with the cohorts administered rsPilA, LB1, chimV4, or dmLT alone.   
      Figure 3                        Resolution of otitis media (OM) in directly challenged middle ears after immunization via a preventative regimen. (  a  ) Immunization with 
rsPilA      +      dmLT, LB1      +      dmLT, or chimV4       +      dmLT induced clearance of nontypeable   Haemophilus influenzae   (NTHI) from middle ears of chinchillas 
compared with the cohorts that received rsPilA, LB1, or chimV4, or the cohort that was immunized with dmLT alone.   *  Statistically significant compared 
with receipt of respective immunogen-only cohort or dmLT-alone cohort (  P        <      0.05). CFU, colony-forming unit; dmLT, double mutant of   E. coli   heat-labile 
enterotoxin; rsPilA, recombinant soluble PilA. (  b  ) Reduction in the percentage of culture-positive middle ears per cohort after receipt of rsPilA      +      dmLT, 
LB1      +      dmLT, or chimV4      +      dmLT relative to the cohorts that received immunogen or dmLT alone.   MucosalImmunology | VOLUME 4 NUMBER 4 | JULY 2011   459
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less) were observed in MEFs collected from animals immunized 
with LB1, rsPilA, or chimV4 that had been admixed with dmLT 
(  P     <    0.05).  Notably,  animals  immunized  with  chimV4    +    dmLT 
resolved OM within 10 days after challenge. 
  In terms of the percentage of animals with culture-positive 
MEFs, similar to that observed in NP lavage fluids, the receipt 
of rsPilA, LB1, chimV4, or dmLT alone resulted in a minimum 
of 10  /  20 ears (50  %  ) with culture-positive MEFs for the entire 
14-day study period in all four cohorts (  Figure 3b ).  However, 
at 3 days after direct challenge of the middle ear, between 80 and 
90  %   of middle ears from animals immunized with any of the 
three immunogens plus dmLT had resolved OM. At 10 days after 
challenge, only 1  /  20 (5  %  ) middle ears in each cohort adminis-
tered LB1 or rsPilA plus dmLT remained culture positive for 
NTHI, and those that received chimV4    +    dmLT had eliminated 
the bacterium from the middle ear. Therefore, these data dem-
onstrated that TCI with the NTHI OMP P5- and Tfp-directed 
candidates delivered with dmLT was efficacious and induced 
elimination of NTHI from the MEFs of challenged animals as 
well as rapid resolution of experimental OM.     
  TCI before NTHI challenge: analysis of antibody in serum 
  To begin to identify the mechanism(s) for the protection 
observed, we first examined the relative quantity of immuno-
gen-specific antibody produced systemically. TCI with any of 
the three immunogens alone induced a fourfold increase in the 
serum antibody geometric mean titer (GMT) of immunogen-
specific IgG and a two- to four-fold increase in specific IgA 
(  Table 1  ) after receipt of all immunizing doses, compared with 
respective preimmune serum. Inclusion of dmLT in each for-
mulation significantly enhanced the resultant GMT (  P     <    0.05), 
as a 16- to 64-fold increase in immunogen-specific IgG and a 
8- to 16-fold increase in specific IgA was detected relative to 
preimmune serum. Based on the ability to eradicate NTHI from 
the NP or middle ear, achieving and maintaining a GMT value 
of at least 160 for immunogen-specific IgG was associated with 
most rapid clearance observed here.     
  Recognition of native proteins expressed by NTHI by 
antibody present within NP lavage fluids induced by a 
preventative immunization regimen 
  Whereas TCI with any of the three candidates induced the 
production of antibody in serum that recognized the immuno-
gen delivered when assayed by enzyme-linked immunosorbent 
assay, we wanted to determine if antibody produced mucosally, 
at the site of NTHI colonization, would bind to native structures 
expressed by viable NTHI, as these structural proteins would be 
the target for the antibodies during disease. By flow cytometry, 
3.5, 3.7, or 1.0 %  more live, unfixed NTHI were positively labeled 
by antibody in NP lavage fluids collected after TCI with LB1, 
rsPilA, or chimV4 alone, respectively, relative to receipt of dmLT 
alone (  Table 2  ). Incubation of NTHI with immune NP lavage 
fluids collected from animals immunized with LB1, rsPilA, 
or chimV4 plus dmLT, however, demonstrated an increase of 
12.6, 11.7, or 10.0  %   in positive labeling of NTHI, respectively, 
compared with dmLT alone. Relative to fluids collected from 
animals that received only immunogen, a 3.2- to 10-fold greater 
labeling of NTHI was achieved when NP lavage fluids from 
immune animals were assayed, which suggested a greater rela-
tive antibody titer and  /  or greater affinity of the antibody for its 
target was present within these mucosal secretions. Thus, TCI 
with the synthetic peptide or recombinant protein immuno-
gens plus dmLT induced the production of mucosal antibody 
that recognized native structures expressed by NTHI that likely 
contributed to the rapid bacterial clearance observed.     
  Resolution of established NTHI biomass in the middle ear via 
use of a therapeutic immunization regimen 
  To examine the therapeutic potential of TCI with the NTHI 
OMP P5- and Tfp-directed immunogens, we now first chal-
lenged chinchillas by direct inoculation of the middle ear with 
NTHI strain 86-028NP and allowed a robust biofilm to form in 
the middle ear space. Previous work has established that when 
    Table 2         Recognition of native proteins expressed by NTHI by 
antibody in NP lavage fluids as assessed by flow cytometry     
        Cohort   
    Percentage of labeled NTHI 
(relative to labeling by serum from 
animals that received dmLT) (  %  )   
      LB1   3.5 
      LB1      +      dmLT   12.6 
          
      rsPilA   3.7 
      rsPilA      +      dmLT   11.7 
          
      chimV4   1.0 
      chimV4      +      dmLT   10.0 
      Abbreviations:     dmLT, double mutant of   E. coli   heat-labile enterotoxin; 
NP, naso  pharynge; NTHI, nontypeable   Haemophilus inﬂ  uenzae  ; 
rsPilA, recombinant soluble PilA.     
      Table 1         Geometric mean titers of immunogen-specific IgG 
and IgA in serum after TCI in a preventative immunization 
regimen     
           Immunogen-speciﬁ  c antibody in serum   
            IgG       IgA   
        Cohort       Pre       Immune       Pre       Immune   
      LB1   10   40   10   40 
      LB1      +      dmLT   10   320*   10   160* 
                   
      rsPilA   10   40   10   40 
      rsPilA      +      dmLT   10   160*   10   80 
                   
      chimV4   10   40   10   20 
      chimV4      +      dmLT   10   640*   10   160* 
      Abbreviations:     dmLT, double mutant of   E. coli   heat-labile enterotoxin; Ig, immuno-
globulin; rsPilA, recombinant soluble PilA; TCI, transcutaneous immunization.     
          *  P        <      0.05 compared with respective immunogen-only titer.     460  VOLUME 4 NUMBER 4 | JULY 2011 | www.nature.com/mi
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using this protocol within 4 days after direct challenge, 83 – 100 %  
of all middle ears develop a biomass that occupies approximately 
75  –  100  %   of the middle ear space. Thus, after these biomasses 
were established, animals were immunized by TCI to deter-
mine if the resulting antibodies could resolve these structures. 
At 1 week after receipt of the second dose, each middle ear was 
blindly ranked based on a 0 to 4       +        scale of relative biomass, 
wherein a score of 0 indicated that no biomass was detected 
within the middle ear space and 4.0    +     designated that 75 – 100 %  
of the middle ear space was filled with biomass. The average 
biomass score for the cohort that received dmLT alone was 2.8, 
which indicated that approximately 50  –  75  %   of the middle ear 
space was filled with biomass ( Figure 4 ). In contrast, use of the 
therapeutic immunization regimen with LB1, rsPilA, or chimV4, 
alone or delivered with dmLT, resulted in a significantly reduced 
biomass (  P     <    0.05).  The  average  biomass  score  after  receipt  of 
LB1 or rsPilA, alone or with dmLT, was between 0.9 and 1.2, 
and thus 75  %   of the biomass had resolved after TCI. Receipt 
of chimV4 alone or with dmLT resulted in greater reduction 
in the relative biomass scores to 0.6 and 0.3, respectively. Based 
on relative biomass score alone, the addition of dmLT did 
not appear to significantly influence the outcome achieved in 
immunized animals. Nonetheless, overall, therapeutic immuni-
zation with the OMP P5- and Tfp-targeted immunogens elicited 
an immune response that resulted in a significant reduction in 
biomass within the middle ear.     
  Induction of immunogen-specific IgG and IgA in serum and 
MEFs after immunization by a therapeutic regimen 
  After TCI as a therapeutic regimen, predominantly 
immunogen-specific IgG was detected in serum from animals 
that received LB1, rsPilA, or chimV4 admixed with dmLT, with 
GMT that was 4- to 16-times greater compared with that of 
animals administered respective immunogen alone (  Table 3 ). 
Within MEFs, again, IgG was the predominant antibody isotype 
observed, and inclusion of dmLT in each vaccine formulation 
resulted in a four- to eight-fold increase in specific antibody 
compared with cohorts administered immunogen alone. Similar 
to that observed after TCI via a preventative immunization regi-
men (shown in   Table 1  ), a GMT of      160 was associated with 
enhanced resolution of biomasses within the middle ears. No 
consistent trend was observed with regard to biomass resolution 
for immunogen-specific IgA in either serum or MEFs recovered 
from immune animals. Thus, TCI via a therapeutic immuni-
zation regimen induced the production of both systemic and 
mucosal antibody (primarily IgG), which likely contributed to 
the observed resolution of NTHI-induced biomass from the 
middle  ear.   
  Resolution of MEFs after TCI via a therapeutic immunization 
regimen 
 As an additional and clinically relevant assessment for the reso-
lution of established NTHI-induced OM, each tympanic mem-
brane was observed to document signs of OM before killing. 
Specifically, video otoscopy and tympanometry were performed 
and relative signs of inflammation and presence of MEFs behind 
the tympanic membrane were scored 14 days after NTHI chal-
lenge. In the cohort that received dmLT alone, 100  %   (6  /  6) of 
ears were positive for the presence of MEFs (  Figure 5 ). Receipt 
of LB1 alone or when delivered with dmLT induced a 17  –  33  %   
reduction in the number of ears with signs of OM, respectively. 
Moreover, a 33 – 50 %  reduction in middle ears with signs of OM 
was achieved after immunization with rsPilA or with chimV4 
alone, respectively. It is noteworthy that immunization via a 
therapeutic  regimen  with  rsPilA    +    dmLT  resulted  in  66 %   fewer 
ears with signs of OM, whereas no MEFs were observed behind 
    Figure 4                        Mean nontypeable   Haemophilus influenzae   (NTHI) biomass 
scores for each bulla after transcutaneous immunization (TCI) following 
a therapeutic regimen, based on blinded evaluation and ranked on a 0 to 
4      +       scale of relative residual biomass.   *  Statistically significant compared 
with receipt of dmLT alone (  P        <      0.05). Receipt of LB1, rsPilA, or chimV4, 
admixed with dmLT, resulted in significantly enhanced resolution of NTHI 
biofilms established within the middle ear space. dmLT, double mutant of 
  E. coli   heat-labile enterotoxin; rsPilA, recombinant soluble PilA.    
    Table 3         Geometric mean titers of immunogen-specific 
IgG and IgA in serum and MEF after TCI in a therapeutic 
immunization regimen     
           Immunogen-speciﬁ  c 
antibody in serum   
    Immunogen-speciﬁ  c 
antibody in MEF   
        Cohort        IgG       IgA       IgG       IgA   
      LB1   40   40   20   10 
      LB1      +      dmLT   160*   20   80   40 
                   
      rsPilA   80   20   20   10 
      rsPilA      +      dmLT   320*   40   160*   20 
                   
      chimV4   40   20   40   10 
      chimV4      +      dmLT   640*   160*   320*   20 
      Abbreviations:     dmLT, double mutant of   E. coli   heat-labile enterotoxin; 
Ig, immunoglobulin; MEF, middle ear ﬂ  uid; rsPilA, recombinant soluble PilA; 
TCI, transcutaneous immunization.*  P        <      0.05 compared with respective 
immunogen-only titer.     MucosalImmunology | VOLUME 4 NUMBER 4 | JULY 2011   461
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the tympanic membranes of animals first challenged with NTHI 
and then immunized with chimV4       +       dmLT, each a statistically 
significant result compared with that obtained following immu-
nization with dmLT alone (  P     <    0.05).  Unlike  our  observations 
for biomass reduction alone, wherein we were unable to detect 
the influence of dmLT, here our data showed a greater reduc-
tion in signs of OM after TCI with any of the three immuno-
gens admixed with dmLT, compared with immunogen alone. 
Therefore, TCI after direct challenge of the middle ear resulted 
in resolution of signs of ongoing NTHI-induced OM in addition 
to mediating a marked reduction in resident biomass within the 
middle  ear.   
  Migration of DCs from the pinnae 
  Last, we examined the migration of DCs from the pinna after 
TCI to identify potential sites of immune induction after 
immunization by this route. To do so, the amine-reactive dye 
carboxyfluoroscein succinimidyl ester (CFSE) was applied 
to the pinnae along with each vaccine formulation to allow 
for discrimination among cells resident within lymphoid tissues 
and DCs that had migrated to these sites from the pinnae.  25,26  
We observed that within 1     h after TCI, only 13.6  %   of cells 
isolated from the nasal-associated lymphoid tissue (NALT) of 
animals immunized with adjuvant alone were CFSE      +      CD11c     +       
(  Figure 6a ). In contrast, TCI with either rsPilA, LB1, or chimV4 
each delivered with dmLT resulted in a 2.5- to 5.4-fold relative 
increase (37.2, 34.4, and 72.9  %  , respectively) in the percent-
age of CFSE      +        DCs detected within this lymphoid aggregate 
(  Figure 6b  –  d ).  CFSE     +      CD11c     +        DCs were also detected in the 
axillary and brachial lymph nodes, although only 1.1- to 2.0-
fold more CFSE      +       DCs were observed in lymph nodes after TCI 
with any immunogen vs. the adjuvant alone (data not shown). 
No difference in the percentage of CFSE      +      CD11c     +        DCs within 
the cervical or mediastinal lymph nodes or spleen of animals 
that received an immunogen and those immunized with dmLT 
alone was found at this time point. These data suggested that 
DCs within the pinnae sampled the NTHI adhesin-derived 
immunogens that had been applied to the surface of the 
pinnae and were induced to mature. DC maturation resulted in 
the preferential migration of these cells to primarily the NALT, 
and also the axillary and brachial lymph nodes. 
  Further analysis was performed to distinguish between the 
DC types that migrated to the lymphoid tissues. We specifically 
focused on discrimination between Langerhan ’ s cells vs. dermal 
DCs, the primary antigen-presenting cells found within the skin. 
A total of  ~ 69 %  of CFSE      +       cells within the NALT were positively 
    Figure 5                        Percentage of middle ears with otitis media (OM) in each 
cohort after immunization via a therapeutic regimen, based on video 
otoscopy and tympanometry.   *  Statistically significant compared 
with receipt of dmLT alone (  P        <      0.05). Resolution of signs of OM was 
enhanced after receipt of LB1, rsPilA, chimV4, or LB1      +      dmLT compared 
with receipt of dmLT alone. Furthermore, resolution of disease signs was 
significantly greater after receipt of rsPilA      +      dmLT or of chimV4      +      dmLT 
compared with administration of dmLT alone. dmLT, double mutant of 
  E. coli   heat-labile enterotoxin; rsPilA, recombinant soluble PilA.    
            Figure 6                        Migration of dendritic cells (DCs) from the pinnae to the 
nontypeable   Haemophilus influenzae   (NALT) after transcutaneous 
immunization (TCI) and discrimination of cutaneous DC cell type. 
Presence of CD11c        +        CFSE        +         cells in the NALT after TCI with 
(  a  ) dmLT alone, (  b  ) rsPilA      +      dmLT, (  c  ) LB1      +      dmLT, or (  d  ) chimV4      +      dmLT 
was detected by flow cytometry. Numbers in each box represent the 
percentage of CFSE        +         cells within each sample. (  e  ) CFSE        +         cells were 
identified to be DC-SIGN        +         dermal DCs. (  f  ) Bone marrow-derived DCs 
activated with chimV4      +      dmLT   ex vivo   and then injected subdermally 
into pinnae migrated to the NALT, whereas dmLT-activated DCs did 
not (inset). CFSE, carboxyfluoroscein succinimidyl ester; dmLT, double 
mutant of   E. coli   heat-labile enterotoxin; FSC, forward scatter; rsPilA, 
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labeled with antibody directed against dendritic cell-specific 
intercellular adehsion molecule-3 grabbing integrin (DC-SIGN), 
specific for dermal DCs,  27   as opposed to 0.3  %   of cells that 
labeled positively for CD207, which is selectively expressed by 
Langerhan ’ s  cells 28   ( Figure 6e  ). Therefore, these data indicated 
that the primary antigen-presenting cells involved in induction 
of the immune responses observed herein were DCs. 
  To further confirm that the positive signal described above 
was because of the migration of DCs to lymphoid tissues and 
not because of diffusion of the dye alone through the lymphat-
ics to that site, we labeled bone marrow-derived DCs with 
CFSE,  activated  them  with  chimV4    +    dmLT  or  dmLT  alone 
  in vitro  , and then injected the DCs intradermally into the 
pinnae. After 1     h, a population of CFSE      +        cells was detected 
within the NALT after receipt of DCs activated with 
chimV4    +    dmLT ( Figure 6f ), but not when activated with dmLT 
alone ( Figure 6f , inset). Moreover, 4.3 %  of the cells isolated from 
the NALT were CFSE      +      ,  whereas       0.6 %   was  observed  within 
the cervical, axillary, and brachial lymph nodes and spleen 
(data not shown). Thus, the migration of DCs resident within 
the pinnae after TCI and those instilled into the pinnae after 
  in vitro   activation were similar, a result that suggested prefer-
ential homing to this local lymphoid aggregate as mediated via 
local cytokine / chemokine signals. Collectively, our tracking data 
demonstrated that immunogen-activated DCs within the pinnae 
migrated primarily to a proximal lymphoid aggregate, the NALT. 
Moreover, the cell type activated after TCI was the dermal DC, 
which likely had a critical role in the initiation of the protective 
immune  response  observed  herein.    
  DISCUSSION 
  OM is a prevalent disease of children worldwide, and although 
commonly managed by prescription of antibiotics and surgical 
intervention where available, the incidence and cost attributed to 
this disease is substantial.  2  Moreover, the emergence of multiple 
antibiotic-resistant bacteria, including strains of NTHI, is a cause 
for concern.  29  Thus, immunization against OM has the potential 
to alleviate this socioeconomic burden by prevention or resolu-
tion of disease. At present, a licensed 10-valent pneumococcal 
capsular conjugate vaccine wherein NTHI protein D serves 
as a carrier molecule (Synflorix, GlaxoSmithKline, Rixensart, 
Belgium) has demonstrated 35.3  %   protective efficacy against 
NTHI-induced OM after parenteral immunization of children 
in a clinical trial in Slovakia and the Czech Republic.  30  Although 
shown as a secondary outcome measure, this trial nonetheless 
demonstrated, for the first time, that parenteral delivery of a 
NTHI-derived antigen could provide protection against OM 
due to NTHI. To increase the modest coverage observed against 
NTHI-induced OM, examination of additional NTHI-specific 
targets is needed. 
  We have focused our vaccine development efforts on two 
of multiple adhesins expressed by NTHI, OMP P5 and Tfp, 
and recently utilized an established chinchilla model of 
viral-bacterial superinfection shown to be predictive of 
the aforementioned clinical trial outcome.  7,31   Collectively, 
these preclinical data demonstrated that antibody induced by 
parenteral immunization with NTHI OMP P5- and Tfp-derived 
vaccine candidates (called LB1, rsPilA, and chimV4) provides 
significant protection against experimental NTHI-induced 
OM.  6   We now sought to expand our vaccine delivery routes 
to include noninvasive administration regimens. Currently, 
children in the United States receive up to 25 vaccines by injec-
tion during the first 2 years of life.  32   This can be cause for 
concern by parents who may ultimately delay or refuse immu-
nization of their child. Also, although not of considerable con-
cern in developed countries, the reuse of needles in developing 
countries poses serious risk for transmission of blood-borne 
diseases.  33,34  Thus, although vaccination by injection is proven 
to be extremely effective as a preventative intervention, deve-
lopment of alternative delivery strategies for current or future 
formulations could potentially serve as equally effective means 
to induce protective immunity while simultaneously addressing 
bottlenecks associated with injectable vaccines. 
  TCI is a simple and noninvasive method for vaccine admin-
istration. In addition to the ease of delivery, both systemic 
and mucosal immunity is induced by this regimen. OM is a 
disease of the uppermost respiratory tract mucosa, and thus 
the potential to initiate mucosal immunity, particularly in the 
nasopharynx where NTHI normally reside, holds promise to 
limit or prevent its onset. We focused on the chinchilla pinnae 
as an easily accessible site for administration that did not require 
manipulation, such as shaving, before delivery. Moreover, as 
there is greater appreciation for compartmentalization within 
the mucosal immune system because of homing of immune cells 
that results in the most powerful response induced at the site 
proximal to delivery,  35,36   we wanted to favor development of 
an immune response in proximity to the NP and middle ear. 
This premise is supported by work in a murine host, where after 
TCI, the greatest cytotoxic lymphocyte activity was detected by 
cells isolated from lymphoid tissues in close proximity to site of 
administration whereas less activity was observed by cells from 
distal tissues.  11  
 A proof-of-concept study demonstrated that TCI induced an 
immunogen-specific immune response in the chinchilla host, 
and that bilateral (both pinnae) administration induced more 
robust immunity compared with unilateral delivery (one pinna; 
data not shown). Furthermore, upon challenge with NTHI, 
we observed clearance of NTHI from the NP and middle ear. 
Herein, we expanded upon that preliminary study to exam-
ine the protection afforded by TCI with the OMP P5-derived 
candidate LB1, the Tfp-directed candidate rsPilA, and the 
chimeric OMP P5- plus Tfp-directed immunogen chimV4 when 
delivered with dmLT, a potent adjuvant. 
  Our current data demonstrated that TCI before NTHI chal-
lenge with any of the three immunogens induced the produc-
tion of both immunogen-specific IgA and IgG and although 
clearance of NTHI was associated with the production of both 
antibody isotypes, a greater relative quantity of IgG was con-
sistently observed. NTHI possess the   iga   gene that encodes an 
IgA1 protease, and up to a third of strains have an additional 
gene (  igaB  ) that encodes a second IgA protease.  37,38   Whereas 
IgA is the conventional antibody isotype detected at mucosal MucosalImmunology | VOLUME 4 NUMBER 4 | JULY 2011   463
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surfaces, mucosal IgG, either produced locally or present via 
transudation from serum, is also known to contribute to pro-
tection against mucosal infection.  35   We observed a correlation 
between antibody GMT of      160 and enhanced resolution of 
disease after TCI via use of a preventative or therapeutic regi-
men. Protection against NTHI-induced OM is primarily anti-
body mediated, although the contribution of T-cell-mediated 
mechanism cannot be ruled out, as it is required for clearance 
of NTHI from the rat lung.  39   The data presented herein dem-
onstrated that TCI induced the production of antibodies that 
targeted adhesins expressed by NTHI and, as such, was likely 
the primary mechanism for eradication of the bacterium from 
the nasopharynx and middle ear. 
  TCI before bacterial challenge with rsPilA, LB1, or chimV4 
delivered with dmLT resulted in a rapid reduction in the bacte-
rial load of NTHI within the NP of immune chinchillas, in addi-
tion to a reduction in the percentage of culture-positive animals 
per cohort, compared with receipt of immunogen or adjuvant 
alone. Within middle ears, whereas an increase in bacterial con-
centration is typically observed after direct challenge because 
of initial bacterial replication,  24   only a modest initial increase 
in CFU NTHI was observed in cohorts that received any of 
the three immunogens plus dmLT and was followed by a rapid 
elimination of bacteria from the middle ear. These data clearly 
demonstrated that TCI with OMP P5 or Tfp-targeted immu-
nogens with dmLT induced an efficacious immune response. 
Among these three cohorts, differences were observed specific 
to the time to clear NTHI from the NP and middle ear after 
challenge. It is known that OMP P5 is constitutively expressed 
and is important for enabling NTHI to establish colonization 
in the NP.  40   NTHI Tfp are temporally expressed and necessary 
for NTHI to maintain long-term colonization at this site.  22  
Moreover, these adhesins are utilized for both adherence and 
biofilm formation within the middle ear. Thus, the presence of 
antibody specific to each adhesin, or both adhesins, likely served 
to prevent NTHI adherence, which facilitated elimination of 
NTHI from the NP and middle ear upon challenge. 
 OM can be a chronic and / or recurrent disease, a consequence 
of biofilms established by NTHI within the middle ear. Based on 
the efficacy afforded by immunization with the OMP P5- and 
Tfp-targeted immunogens before bacterial challenge, we won-
dered whether TCI after NTHI challenge might also effectively 
resolve OM by eradicating an already established NTHI biofilm 
from the middle ear. Immunization via a therapeutic regimen 
resulted in a reduction in the signs of OM based on a clinically 
relevant scoring system, in addition to overall resolution of an 
established NTHI biomass in the middle ear as determined by 
blinded gross examination of the middle ear space. Whereas a 
significant reduction in biomass was grossly observed for all 
immune animals compared with those that received dmLT 
alone, only cohorts that received rsPilA or chimV4 admixed 
with dmLT demonstrated a significant reduction in signs of 
disease as determined by video otoscopy and tympanometry. 
The two techniques, one of gross examination and the other 
of observation for signs of disease, do not discredit each other. 
Rather, they indicated that whereas TCI via a therapeutic route 
resulted in reduction of middle ear biomass, MEFs had yet to 
drain through the Eustachian tube or be absorbed by the middle 
ear mucosa in all animals, although overall signs of OM were 
reduced. Therapeutic vaccines for control of other viral or bacte-
rial infections have been examined in experimental and clinical 
trials with promising results,  41 – 43  and currently in use is a thera-
peutic canine melanoma vaccine to combat oral melanoma.  44  
Thus, the strategy to resolve active disease by therapeutic 
vaccination is promising. 
  An additional observation from each study presented herein 
was the enhanced immune response and resultant bacterial 
clearance by formulation of each immunogen with dmLT, com-
pared with administration of immunogen alone. Derivatives of 
cholera toxin and   E. coli   heat-labile enterotoxin have shown 
utility as adjuvants for mucosal and cutaneous immunization 
regimens, wherein the toxicity associated with mucosal applica-
tion of each holotoxin is not observed.  45   Specific to dmLT, the 
engineered amino-acid substitutions at position 192 inactivates 
a trypsin cleavage site and at position 211 modifies a potential 
pepsin cleavage site.  16   The resultant molecule is insensitive to 
proteolysis by either enzyme, as by design. Furthermore, no 
toxicity is observed in a patent mouse enterotoxicity model.  16  
Although the exact mechanism is undefined, it is believed that 
adjuvant activity is an overall outcome of the activation of vari-
ous cell types, including DCs.  46,47  
 We also examined the role of cutaneous DCs in the observed 
rapid and protective immune response. Our data demonstrated 
that TCI with the OMP P5- and Tfp-targeted immunogens 
delivered with dmLT induced the maturation and subsequent 
migration of DCs resident within the pinnae, a response not 
observed after application of dmLT alone. As a complimentary 
approach, DCs activated  ex vivo  and then injected subdermally 
into the pinnae exhibited similar maturation and migration 
characteristics as   in vivo  -activated DCs. By each approach, 
immunogen-activated DCs migrated primarily to the NALT, 
an immune inductive site,  48   likely because of local cytokine  /
  chemokine signaling. Migratory cells within the NALT were 
identified to be predominantly dermal DCs, not Langerhan  ’  s 
cells, based on the expression of DC-SIGN vs. CD207. Although 
not completely defined, it is proposed that Langerhan  ’  s cells 
are responsible for tolerogenic immunity, i.e., to self-antigens, 
whereas dermal DCs are involved in development of protective 
immunity.  49  Moreover, compared with Langerhan ’ s cells, dermal 
DCs exhibit faster migration and populate lymph nodes in areas 
closer to B-cell follicles,  50   facilitating antigen presentation to B 
cells and initiation of immune responses. Therefore, TCI served 
to engage dermal DCs within the chinchilla pinnae that facili-
tated the development of a local and systemic immune response. 
We continue to examine the contribution of additional innate 
immune effector to the rapid resolution observed herein. 
  As we continue to develop TCI as a delivery method, it is 
important to consider the practical application of this method 
to humans, particularly to very young children. To promote 
deve  lopment of a mucosal immune response in the uppermost 
airway of a child, it is rational to propose vaccine application to 
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the Waldeyer ’ s tonsillar ring in the neck and pharynx functions 
similar to the rodent NALT, and thus the potential exists to 
induce an immune response within lymphoid tissues proxi-
mal to the human nasopharynx and middle ear, as desired. 
Furthermore, to facilitate widespread application, the TCI 
method must be simple and inexpensive, preferably device-
less, and yet be able to efficiently deliver the formulation to 
the dermal DCs through the   stratum corneum  . Whereas there 
are multiple strategies in development to breach this protective 
barrier,  51   we suggest that direct application of a gel or cream 
on to the skin also has the potential to hydrate the stratum 
corneum, restrict diffusion of the antigen, and promote 
long-term sampling by DCs. 
  In summary, TCI served to engage dermal DCs within 
the chinchilla pinnae that resulted in the development of a 
local mucosal, in addition to systemic, immune response. 
Administration of the NTHI OMP P5- and Tfp-directed immu-
nogens admixed with dmLT was efficacious to both prevent 
experimental NTHI-induced OM and to resolve active OM. 
These data therefore demonstrated that TCI is an effective way 
to immunize against experimental NTHI-induced OM and has 
potential application to prevent other diseases of the respira-
tory tract due to NTHI. Moreover, the reduced costs associated 
with noninvasive routes of immunization such as TCI hold great 
promise in terms of expanding the use of vaccines to prevent 
OM beyond the boundaries of developed countries.     
  METHODS 
    Animals 
 To examine the efficacy of TCI utilized as a preventative immunization 
strategy, 70 adult chinchillas ( Chinchilla lanigera;  Rauscher ’ s Chinchilla 
Ranch, LaRue, OH; mean mass 662  ±  15     g) with no evidence of middle 
ear disease as determined by video otoscopy (MedRx, Largo, FL) and 
tympanometry (EarScan, Murphy, NC) were enrolled and divided into 
7 cohorts of 10 animals each. To test TCI as a therapeutic immunization 
strategy, 21 adult chinchillas (625 ± 23   g) were enrolled and divided into 
7 cohorts of 3 animals each. Animal care and all procedures were per-
formed in concordance with institutional and federal guidelines, and 
were conducted under an approved protocol.   
  Immunogens and adjuvant 
  NTHI OMP P5 was observed expressed by 100  %   of a panel of middle 
ear and nasopharyngeal NTHI isolates collected from children with 
chronic OM.  52  Multiple algorithmic analyses of the deduced amino-acid 
sequence of OMP P5 predict four surface-exposed regions within the 
N-terminus of this adhesin,  53,54   and within the third surface-exposed 
region is a 19-mer B-cell epitope that is incorporated into LB1.  55  Among 
NTHI strains tested, there is limited amino-acid sequence diversity 
within this moiety that allows for segregation of isolates into three groups, 
76 %  of which cluster into one majority group. The immunogen LB1 is a 
40-mer synthetic chimeric peptide comprising the aforementioned 
19-mer B-cell epitope from OMP P5 that is colinearly synthesized with 
a T-cell promiscuous epitope from measles virus fusion protein, incor-
porated to be broadly permissive in binding to major histocompatibility 
complex class II molecules. 
 PilA, the majority subunit of NTHI Tfp, has minimal deduced amino-
acid sequence diversity. Among a panel of 23 isolates tested, the prod-
uct of the   pilA   gene exhibits      81  %   sequence identity to that of NTHI 
strain 86-028NP.  56   Recombinant, soluble PilA (rsPilA) is a 122 amino-
acid recombinant protein that represents a mature, N-terminally trun-
cated PilA subunit of the NTHI Tfp.  6,22,56   ChimV4 is a novel, chimeric 
immunogen wherein modified rsPilA serves as an immunogenic 
carrier for a slightly larger (24 amino acids) variant of the OMP P5 B-cell 
epitope described within the immunogen LB1.  6  A double mutant form of 
  E. coli  heat-labile enterotoxin, called LT(R192G-L211A) and abbreviated 
dmLT, wherein glycine is substituted for arginine at position 192 and 
alanine is substituted for lysine at position 211, served as the adjuvant.  16  
The amino-acid substitutions render dmLT nontoxic while maintaining 
its adjuvant properties.    
  NTHI strain 
  NTHI strain 86-028NP was isolated from the nasopharynx of a child 
undergoing tympanostomy and tube insertion for chronic OM at 
Nationwide Children  ’  s Hospital, Columbus, OH. This strain has been 
characterized and extensively used in chinchilla models of OM and a rat 
model of pulmonary clearance.  7,24,31,57    
  Immunization via a preventative regimen and NTHI challenge 
 TCI via a preventative immunization regimen was performed as follows: 
both pinnae of each alert animal were hydrated for 5     min by placement 
of gauze soaked in sterile, pyrogen-free 0.9 %  sodium chloride (Hospira, 
Lake Forest, IL) on the inner surface before vaccination. The inner 
surface of each pinna was then blotted with dry gauze and 50        l  of 
each vaccine formulation was applied using a pipet. The pinnae were 
then folded in half and opposing surfaces gently rubbed together. 
Formulations consisted of 10         g LB1, rsPilA, or chimV4 delivered 
alone or admixed with 10        g  LT(R192G-L211A),  also  called   “ dmLT, ”  
or  10      g dmLT alone. Two doses were delivered at weekly intervals. 
NTHI challenge was performed as previously described.  24   Briefly, at 
1 week after receipt of the second immunizing dose, all chinchillas 
were challenged intra  nasally with 10  8    CFU  NTHI  strain  86-028NP 
delivered in 0.2     ml pyrogen-free saline divided equally between the 
nares, as well as transbullarly with 1,000     CFU NTHI delivered in 0.3     ml 
sterile pyrogen-free saline per bulla. Challenge doses were confirmed 
by plate count.    
  NTHI challenge and immunization via a therapeutic strategy 
 TCI following a therapeutic regimen involved challenge of all chinchillas 
exclusively transbullarly with 1,000     CFU NTHI strain 86-028NP before 
immunization. At 4 days after NTHI challenge, animals were immunized 
by TCI as described above. Formulations consisted of 10     g LB1, rsPilA, 
or chimV4 delivered alone or admixed with 10     g dmLT or 10     g dmLT 
alone and were delivered twice at weekly intervals. At 1 week after receipt 
of the second immunizing dose, all animals were killed.    
  Histology of chinchilla pinnae 
 Pinnae were collected and trimmed to the central 2.5   mm  2  portion. The 
pinna was then cut into four strips of equal size and fixed in 2  %   w  /  v 
paraformaldehyde in 0.1    m  phosphate buffer, pH 7.4, for 24   h. Strips were 
processed for routine histology and embedded in paraffin. Serial sections 
(5     m) were cut and tissue stained with hematoxylin and eosin.    
  Collection of blood and mucosal secretions 
 Blood for serum was collected via cardiac puncture before immunization 
(pre) and 1 week after receipt of the second immunizing dose (immune) 
for all animals immunized via a preventative regimen. Animals immu-
nized via a therapeutic regimen were bled before NTHI challenge and 
at study end. 
 NP lavages were performed on animals immunized via a preventative 
regimen before immunization, 1 week after receipt of the final dose, and 
on days 3, 7, 10, and 14 after bacterial challenge by passive inhalation of 
500     l sterile pyrogen-free saline as previously described.  24  
 Video otoscopy (using a 0 ° , 3-inch probe connected to a digital camera 
system) to monitor signs of tympanic membrane inflammation and  /  or 
presence of fluid within the middle ear space was performed and overall 
signs of OM were rated on a scale of 0 to 4    +     as previously described.  7,24,31  
Middle ears with a score of     2.0 were always considered positive for OM 
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considered independent, and for each cohort, the percentage of middle 
ears with OM was calculated. 
 Epitympanic taps to retrieve middle ear effusions were performed on 
any chinchilla whose tympanic membrane was rated as      2.5 on a scale 
of 0 to        +       4.0. Epitympanic taps were not performed on ears ranked 2.0, 
due potential for perforation of the tympanic membrane to retrieve the 
low volume of MEF. NP lavage and MEFs were serially diluted and plated 
onto chocolate agar supplemented with 15     g ampicillin per ml medium 
or chocolate agar, respectively, to semiquantitate CFU NTHI per ml fluid 
type. The mean CFU NTHI per ml fluid was reported for each cohort.    
  Evaluation of middle ear biomass 
  Upon killing of animals immunized after NTHI challenge, the inferior 
bullae from each animal were dissected, opened to reveal the middle 
ear space, and washed with 1     ml sterile, pyrogen-free saline to remove 
residual MEF and loosely adherent biomass. The bullae and remaining 
adherent biomass were then imaged with a digital camera. The images 
from the left and right bulla were scrambled and scored by nine blinded 
observers who ranked the relative residual biomass on a 0 to 4       +        scale, 
wherein  0    =    no  biomass;  1    =      biomass  fills      <    25 %   of  middle  ear  space; 
2    =    biomass fills 25 – 50 %  of middle ear space; 3    =    biomass fills 50 – 75 %  of 
middle ear space; and 4    =    biomass fill 75 – 100 %  of middle ear space. The 
mean biomass score for each bulla was reported.    
  Enzyme-linked immunosorbent assay 
 Enzyme-linked immunosorbent assay was performed on serum to detect 
immunogen-specific IgG and IgA in immune serum and MEFs. Samples 
were incubated in LB1-, rsPilA-, or chimV4-coated wells (0.2     g protein 
per well) for 3     h at 25       °  C and antibody was detected with horseradish 
peroxidase-conjugated goat anti-rat IgG or IgA (Bethyl Laboratories, 
Montgomery, TX). Color was developed with 3,3    ,5,5   -tetramethyl-
benzidine (Pierce Biotechnology, Rockford, IL). Reciprocal titers were 
defined as the dilution that yielded an OD  450   nm  value of 0.1 above control 
wells that were incubated without sample fluids. Assays were performed a 
minimum of three times and reciprocal titers reported as the GMT.    
  Flow cytometry to detect recognition of native proteins on 
NTHI 
  To detect the recognition of native OMP P5 and Tfp as expressed on 
the surface of NTHI by antibodies in NP lavage fluids, flow cytometric 
analysis was performed. NTHI strain 86-028NP was cultured overnight 
on chocolate agar, and then suspended in brain heart infusion broth 
supplemented with 2         g each of     -NAD and heme (Sigma Aldrich, 
St Louis, MO). The optical density was adjusted to 0.6 at 490   nm, further 
diluted 1:6 in fresh supplemented brain heart infusion broth, and the 
culture incubated static for 3     h at 37       °  C, previously shown to be time of 
maximal  pil  promoter activity. 56  NTHI were then incubated with a 1:10 
dilution of pooled clarified NP lavage fluids for 1   h at 37    ° C on a rotational 
rocker. Chinchilla immunoglobulins were detected with Protein A conju-
gated to fluorescein isothiocyanate (Zymed, South San Francisco, CA). A 
total of 20,000 events were collected per sample using a FACSCalibur flow 
cytometer (Becton Dickinson, Franklin Lakes, NJ) and data analyzed 
with FlowJo software (Tree Star, Ashland, OR). Assays were performed 
a minimum of three times.    
    In vivo   migration of DCs from the pinnae 
 To track the migration of chinchilla DCs from the pinnae to lymphoid tis-
sues, we applied the amine-reactive vital dye, CFSE (Invitrogen, Carlsbad, 
CA)  with  LB1    +    dmLT,  rsPilA    +    dmLT,  chimV4    +    dmLT,  or  dmLT  alone 
to passively label cells that sampled the vaccine formulations after deliv-
ery.  25,26  To confirm a minimal contribution of nonspecific activation of 
DCs by the dye itself, CFSE alone was also applied. At 1   h after TCI with 
vaccine formulations and CFSE, animals were killed and the cervical, 
brachial, axillary, and mediastinal lymph nodes were removed in addition 
to the spleen. The NALT was also removed. Tissues were crushed into 
Dulbecco  ’  s phosphate-buffered saline without calcium or magnesium 
(Mediatech, Manassas, VA) and cells passed through a 40     m cell strainer. 
The spleen was also crushed, strained, and the cells centrifuged with 
Ficoll-Paque. DCs were labeled with mouse anti-rat CD11c-Alexa fluor 
647 (AbD Serotec, Raleigh, NC) and CD11c      +       CFSE     +       cells were detected 
by flow cytometry. A total of 10,000 events were collected. 
  To discriminate between Langerhan  ’  s cells and dermal DCs, 10  6   cells 
from each lymphoid tissue cell suspension were incubated with mouse 
anti-human DC-SIGN-APC, and then permeabilized and incubated 
with mouse anti-human CD207-PE (R  &  D Systems, Minneapolis, MN) 
or appropriate isotype control antibody and assayed via flow cytometry. A 
total of 10,000 events were collected. Assays were performed a minimum 
of three times and representative scatter plot shown. 
 To confirm that the CFSE      +       signal detected within the NALT was spe-
cifically because of the migration of DCs from the pinnae and not because 
of diffusion of the dye within the lymphatics, we investigated whether 
  in vitro  -activated, bone marrow-derived DCs would similarly follow 
homing signals to the NALT when applied to the pinnae. Thus, chinchilla 
bone marrow cells were harvested and cultured in the presence of 40   ng 
each of human recombinant granulocyte-macrophage colony-stimulating 
factor and interleukin-4 (R & D Systems) per ml to induce differentiation 
of precursor cells as previously described.  26   After 6 days, the immature 
DCs were labeled with 10           m   CFSE before incubation for 30     min with 
either 10     g chimV4 plus 10     g dmLT or 10     g dmLT alone. The treated 
DCs were washed to remove unbound immunogen, adjusted to 10  6  cells 
per  100      l, and injected intradermally to alert chinchillas in a volume 
of  50      l per pinna. The animals were killed 1     h later, and the lymphoid 
tissues were processed as described above. CFSE      +       cells were detected by 
flow cytometry. A total of 10,000 viable events were collected for each of 
three independent assays and representative plots are shown.    
  Statistics 
  Statistical differences between antibody titers, bacterial counts in NP 
lavage fluids, and MEFs were determined using Kruskal  –  Wallis one-
way analysis of variance on ranks and Dunn ’ s method for multiple com-
parisons. A   P  -value of      0.05 was considered significant. Significant 
differences in relative biomass among cohorts and percentage of middle 
ears with OM were assessed by a repeated measures analysis of vari-
ance and Bonferroni ’ s multiple comparison test. A  P -value of     0.05 was 
considered significant.      
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